-

Catalent, Inc. Announces Second Quarter Fiscal Year 2024 Earnings Conference Webcast

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will release financial results for the second quarter of fiscal year 2024 ended December 31, 2023, before the market open on Friday, February 9, 2024. The Company’s management will host a webcast to discuss the results at 8:15 a.m. ET on the same day.

Catalent invites all interested parties to listen to the webcast and view a supplemental slide presentation, both of which will be accessible through Catalent’s website at https://investor.catalent.com. The webcast replay, along with the supplemental slides, will be available for 90 days at https://investor.catalent.com.

About Catalent

Catalent, Inc., is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,500 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply approximately 70 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of nearly 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $4.3 billion in revenue in its 2023 fiscal year.

Contacts

Investor Contact:
Paul Surdez, Catalent, Inc.
(732) 537-6325
investors@catalent.com

Catalent, Inc.

NYSE:CTLT

Release Versions

Contacts

Investor Contact:
Paul Surdez, Catalent, Inc.
(732) 537-6325
investors@catalent.com

More News From Catalent, Inc.

Catalent Completes Successful Debt Refinancing to Support Continued Growth and Innovation

TAMPA, Fla.--(BUSINESS WIRE)--Catalent has completed a significant debt refinancing transaction to support its future growth while reducing its annual interest expenses....

Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of MCO-010

TAMPA, Fla. & DALLAS--(BUSINESS WIRE)--Catalent & Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010...

Catalent Launches Qai™ to Reimagine Quality Assurance for its Manufacturing Services

TAMPA, Fla.--(BUSINESS WIRE)--Catalent announces the launch of Qai, an enterprise AI tool designed to elevate the best quality systems and processes across Catalent’s network....
Back to Newsroom